

Company Factsheet

March 2022

hikma.

Company description

Hikma is a multinational pharmaceutical company. Listed on the London Stock Exchange, we are a global company with a local presence across the US, MENA and Europe, providing our customers with a broad range of generic, specialty and branded pharmaceutical products.

LSE: HIK | NASDAQ Dubai: HIK

Acting responsibly

At Hikma, we strive to put better health, within reach, every day and make a difference to people's lives.

We have a duty to act responsibly: for our people, patients, communities and the planet. We have identified four focus areas where we can drive positive impact.



Key group financials

(Year end December 2021)

Core revenue
2021: \$2,553m
2020: \$2,341m

Core operating profit
2021: \$632m
2020: \$566m

Core EBITDA
2021: \$727m
2020: \$674m


Core basic EPS
2021: 194.8c
2020: 172.9c

DPS
2021: 54c
2020: 50c

Net debt to EBITDA
2021: 0.6x
2020: 0.9x

Core results show the underlying performance of the Group, excluding exceptional items.

% Group core revenue



Strategy

Hikma's strategy is to deliver high quality, affordable medicines and make healthcare more accessible to patients by delivering more from its strong foundation, inspiring and enabling its people, and building a portfolio that anticipates future health needs across its three business segments.



Injectables

We supply hospitals across our markets with generic injectables, supported by our manufacturing facilities in the US, Europe and MENA. In the US, we have broadened our product offering to include compounded sterile injectables.



Generics


We supply oral and other non-injectable generic and specialty branded products in the US retail market, leveraging our state-of-art manufacturing facility in Columbus, Ohio.



Branded

We supply branded generics and in-licensed patented products from our local manufacturing facilities to retail and hospital customers across the MENA region.

Company strengths



Unique and diversified business model



Injectables 41%
Generics 32%
Branded 26%



Strong market position

#2

generic injectable manufacturer in the US

#4

pharmaceutical company in MENA



Commitment to quality

13

US FDA inspected plants

12

EMA-inspected plants



Large and growing pipeline

280+

Products in our pipeline



17.1%
ROIC


Return on invested capital¹

1. Return on invested capital is calculated as core operating profit after interest and tax divided by invested capital (calculated as total equity plus net debt).

Injectables



Core Revenue



Core Op. Profit



Key focus areas

- Continue to grow our base business through our scale and strength of customer relationships
- New product launches – launched 15 products in the US in 2021
- Drive demand in MENA and Europe, including through biosimilars and use of HCO facility in Portugal

Products: Includes anti-infectives, pain management, cardiovascular, oncology, compounded sterile injectables

Customers: Includes hospitals, Group Purchasing Organisations, Civica Rx

Capabilities: Includes sterile liquid, powder, lyophilised and cytotoxic products, in a broad range of forms, including vials, ampules, bags and prefilled syringes, manufactured in facilities in the US, Portugal, Germany, Italy and MENA

Generics



Core Revenue



Core Op. Profit



Key focus areas

- Differentiation – offer broad portfolio of differentiated products, including nasal sprays and respiratory
- Quality and operational efficiencies – world-class FDA-inspected facilities
- Pipeline – focus on adding complex and specialty products through R&D and partnerships

Products: Broad product portfolio encompassing oral solids and liquids and leader in US prescription nasal sprays

Customers: 90% of retail generics bought by three customer consortia

Capabilities: State of the art facility in Columbus Ohio, as well as US FDA-inspected facilities in Saudi Arabia and Jordan

Branded



Core Revenue



Core Op. Profit



Key focus areas

- We operate in 18 markets across the MENA region, with a tiered approach, focusing on the highest value markets (Tier 1: Saudi Arabia, Algeria, Egypt)
- R&D is focused on key markets and therapeutic areas where we see value
- Partnerships are a key contributor to this business and we work hard to maintain our partner of choice status with global innovative pharma companies

Products: Broad portfolio of branded generics and in-licensed products – we are the partner of choice in the region

Customers: Pharmacies and hospitals across the region

Capabilities: Manufacturing facilities in seven countries, many of which are both locally approved, and US FDA and EMA-approved. 2,000 sales representatives and support staff across our 18 markets

Company information

CEO: Siggí Olafsson

CFO: Khalid Nabils

Hikma Pharmaceuticals PLC
1 New Burlington Place
London W1S 2HR

Contacts

Press: mediainquiries@hikma.com

Investor Relations: UK-Investors@Hikma.com